Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin
| Autor: | Frédéric Marchal, Jean-Marc Classe, Dominique Elias, Julia Bonastre, Julie Chevalier, Jean-Marc Guilloit, Diane Goéré, Antoine Brouquet, Gwenael Ferron, Jérémie H. Lefevre, Pierre Meeus |
|---|---|
| Přispěvatelé: | Institut Gustave Roussy (IGR), Centre de Recherche en Automatique de Nancy (CRAN), Université Henri Poincaré - Nancy 1 (UHP)-Institut National Polytechnique de Lorraine (INPL)-Centre National de la Recherche Scientifique (CNRS), Centre Alexis Vautrin (CAV), Centre René Gauducheau, CRLCC René Gauducheau, Institut Claudius Regaud, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre Léon Bérard [Lyon] |
| Rok vydání: | 2009 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Organoplatinum Compounds Antineoplastic Agents Adenocarcinoma 030230 surgery Irinotecan 03 medical and health sciences 0302 clinical medicine medicine Humans Combined Modality Therapy Survival rate Peritoneal Neoplasms Retrospective Studies business.industry Carcinoma Cancer Retrospective cohort study Hyperthermia Induced Middle Aged medicine.disease Antineoplastic Agents Phytogenic 3. Good health Oxaliplatin Surgery [SDV.BBM.BP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biophysics Survival Rate Oncology 030220 oncology & carcinogenesis Peritoneal Cancer Index Camptothecin Female Hyperthermic intraperitoneal chemotherapy Colorectal Neoplasms business medicine.drug |
| Zdroj: | Journal of Clinical Oncology Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (5), pp.681-685. ⟨10.1200/JCO.2008.19.7160⟩ |
| ISSN: | 1527-7755 0732-183X |
| Popis: | Purpose To compare the long-term survival of patients with isolated and resectable peritoneal carcinomatosis (PC) in comparable groups of patients treated with systemic chemotherapy containing oxaliplatin or irinotecan or by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Patients and Methods All patients with gross PC from colorectal adenocarcinoma who had undergone cytoreductive surgery plus HIPEC from 1998 to 2003 were evaluated. The standard group was constituted by selecting patients with colorectal PC treated with palliative chemotherapy during the same period, but who had not benefited from HIPEC because the technique was unavailable in the center at that time. Results Forty-eight patients were retrospectively included in the standard group and were compared with 48 patients who had undergone HIPEC and were evaluated prospectively. All characteristics were comparable except age and tumor differentiation. There was no difference in systemic chemotherapy, with a mean of 2.3 lines per patient. Median follow-up was 95.7 months in the standard group versus 63 months in the HIPEC group. Two-year and 5-year overall survival rates were 81% and 51% for the HIPEC group, respectively, and 65% and 13% for the standard group, respectively. Median survival was 23.9 months in the standard group versus 62.7 months in the HIPEC group (P < .05, log-rank test). Conclusion Patients with isolated, resectable PC achieve a median survival of 24 months with modern chemotherapies, but only surgical cytoreduction plus HIPEC is able to prolong median survival to roughly 63 months, with a 5-year survival rate of 51%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|